CRAIGAVON, NORTHERN IRELAND-- Almac Diagnostics will address a collection of international cancer experts at the 4th Annual All Ireland Cancer Conference which will be held at the Four Season’s Hotel Dublin from 30th November to 4th December.
The M.D. of Almac Diagnostics Professor Paul Harkin will present at the forthcoming event as a key speaker on Biomarkers in Prognosis and treatment. Professor Harkin will outline how Almac’s cutting edge technology can accelerate the rapid delivery and development of diagnostic, prognostic and predictive tests to improve the management of cancer patients’ treatment.
The All Ireland Cancer conference, now in its 4th year will include a multi-disciplinary overview of the latest advances in cancer care, from prevention through treatment to end-of-life care, including topics as diverse as communication skills and genome-wide association studies.
As well as M.D. of Almac Diagnostics, Paul Harkin is a Professor of Molecular Oncology within the Cancer Research Centre at Queen’s University Belfast. His research has been published in some of the world’s leading research journals including Cell, Nature Genetics and The Journal of the National Cancer Institute, and Lancet. He also is represented on several National committees and funding boards and acts as a reviewer for a number of major research journals. Speaking about the event he said:
“The advent of high throughput genomic-based technologies has created new opportunities to aid our understanding of the molecular basis of cancer. These technologies are also being harnessed to develop new diagnostic, prognostic and predictive tests that are likely to have a dramatic positive impact on the management of cancer patients’ treatment”.
“At Almac, we are at the cutting edge of technology in this area and work across drug development, target identification, companion diagnostics and predictive and prognostic tests with the aim of aiding research into and improving personalised medical care for cancer patients .”
The conference is organised by the Ireland-Northern Ireland-National Cancer Institute and has attracted internationally renowned speakers in the many areas of basic science, clinical care, cancer nursing, health services research and prevention from North America, Ireland and the UK.
About Almac Diagnostics:
Almac Diagnostics provides translational genomic based solutions for pharma, biotech and academia. Almac specialises in working with fresh and FFPE tissue for generation of predictive and prognostic tests, drug development, target identification and companion diagnostics.
About Almac Group:
The Almac Group comprises five closely integrated divisions offering a broad range of services from R&D, translational genomic services, API manufacture, formulation development, clinical trial supply and technology (IVRS/Web/EDC), to commercial-scale manufacture. Almac provides services to more than 600 companies, including all the world leaders in the pharmaceutical and biotech sectors.
The company has over 2,000 employees and is headquartered in Craigavon, Northern Ireland. US operations are based in Pennsylvania, North Carolina and California. For more information about the Almac Group, please visit www.almacgroup.com.
